Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Accumulated Depreciation: 2019-2022

Historic Accumulated Depreciation for Nurix Therapeutics (NRIX) over the last 2 years, with Aug 2022 value amounting to $18.1 million.

  • Nurix Therapeutics' Accumulated Depreciation rose 28.51% to $18.1 million in Q3 2022 from the same period last year, while for Aug 2022 it was $18.1 million, marking a year-over-year increase of 28.51%. This contributed to the annual value of $14.9 million for FY2021, which is 12.87% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Accumulated Depreciation of $18.1 million as of Q3 2022, which was up 8.73% from $16.7 million recorded in Q2 2022.
  • In the past 5 years, Nurix Therapeutics' Accumulated Depreciation ranged from a high of $18.1 million in Q3 2022 and a low of $11.0 million during Q4 2019.
  • Moreover, its 3-year median value for Accumulated Depreciation was $14.5 million (2021), whereas its average is $14.8 million.
  • Data for Nurix Therapeutics' Accumulated Depreciation shows a peak YoY increased of 28.51% (in 2022) over the last 5 years.
  • Over the past 4 years, Nurix Therapeutics' Accumulated Depreciation (Quarterly) stood at $11.0 million in 2019, then increased by 19.81% to $13.2 million in 2020, then increased by 12.87% to $14.9 million in 2021, then grew by 28.51% to $18.1 million in 2022.
  • Its Accumulated Depreciation was $18.1 million in Q3 2022, compared to $16.7 million in Q2 2022 and $15.7 million in Q1 2022.